DIRS.INFO The most relevant business & tech news

☆ Dolly Parton receives $100 million Courage and Civility Award from Jeff Bezos and Lauren Sanchez
▼ + stars: | 2022-11-12 | by ( Chloe Melas | ) edition.cnn.com time to read: +2 min

CNN —Dolly Parton is the latest recipient of the Bezos Courage and Civility Award. “We can’t wait to see all the good that you’re going to do with this $100 million award, @DollyParton.”Parton, who has donated to various causes for decades, publicly thanked Bezos and Sanchez on Twitter. I will do my best to do good things with this money,” Parton tweeted. Among her philanthropic efforts in her home state of Tennessee, Parton also created the Dolly Parton Scholarship, which provides $15,000 to recipients towards a college education. Last year, Bezos awarded $100 million each to CNN contributor Van Jones and chef José Andrés.

☆ Thanksgiving is two weeks away. Get your updated Covid-19 shot now, health officials warn
▼ + stars: | 2022-11-10 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +8 min

CNN —With Thanksgiving just two weeks away, people who are eligible for an updated Covid-19 vaccine booster but still haven’t received the shot will need to roll up their sleeves Thursday to get as much protection as possible before the holiday. After getting the updated Covid-19 vaccine, that biological process can take about 10 to 14 days. Health officials say it’s fine to get the updated Covid-19 booster and flu vaccine at the same time. The vaccine candidate contains components of the companies’ updated Covid-19 booster and their investigational flu vaccine. Moderna is also developing a combined flu and Covid-19 mRNA vaccine and another combination vaccine targeting flu, Covid-19 and RSV.

☆ Sanofi, GSK score late win with EU COVID booster approval
▼ + stars: | 2022-11-10 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

The shot is based on lab-made viral proteins provided by Sanofi and an adjuvant ingredient from GSK that increases the immune response. Adapting the older protein technology chosen by Sanofi and GSK to a new virus variant requires several months longer than under the mRNA approach, which saw a breakthrough during the pandemic. Work on the shot by Sanofi and GSK, two of the world's largest vaccine makers by sales, was delayed repeatedly. The partners later pivoted to targeting the Beta variant, requiring months in additional development time. While the shot tested at the time was bivalent - meaning it was based both on original Wuhan strain of the virus and Beta - Sanofi and GSK later focused on a monovalent shot based on Beta only.

☆ European regulator recommends Pfizer's Omicron booster for children
▼ + stars: | 2022-11-10 | by ( ) www.reuters.com time to read: 1 min

Nov 10 (Reuters) - Pfizer Inc (PFE.N) and its partner BioNTech said on Thursday the EU health regulator has recommended authorising the use of their bivalent COVID-19 shot as a booster in children aged 5 through 11. The Omicron-tailored vaccine is already authorised by the European Commission for individuals aged 12 years and above. The updated bivalent booster shot targets the original coronavirus strain as well as the BA.4 and BA.5 sub-variants of Omicron. In October, European Medical Agency backed authorization of Moderna Inc's (MRNA.O) COVID-19 tailored booster shots for 12 and above to further vaccination campaigns in the region. Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Shounak Dasgupta amd Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ Novavax posts third quarter loss but beats revenue expectations
▼ + stars: | 2022-11-08 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

In this photo illustration a silhouette of a man holding a medical syringe and a vial seen displayed in front of the Novavax logo on a screen. Novavax posted an unexpected loss on Thursday but beat Wall Street's revenue expectations for the third quarter. The Covid-19 vaccine maker reported a net loss of more than $169 million for the third quarter, compared to a loss of $322 million in the same period last year. Novavax reported third quarter revenue of $735 million, a more than 300% increase year over year. The company previously slashed its annual revenue expectations by 50% to a range of $2 billion to $2.3 billion in the second quarter.

☆ These ETFs can help round out your midterm election investing playbook
▼ + stars: | 2022-11-08 | by ( Jesse Pound | ) www.cnbc.com time to read: +4 min

Even if the election results match expectations, stocks may still rally as some unknowns are removed. Broad sector ETFs from firms like iShares, State Street and Vanguard are one way to play these sectors, offering cheap broad exposure. For example, the Industrial Select Sector SPDR ETF (XLI) and Vanguard Communications Services ETF (VOX) both have an expense ratio of 0.10%. Under-the-radar elections Federal elections are not the only contests on Tuesday that could move stocks. The biggest marijuana ETFs — AdvisorShares Pure US Cannabis ETF (MSOS) and ETFMG Alternative Harvest ETF (MJ) — are each down more than 50% for the year.

☆ Novavax says Omicron shot shows strong immune response as second booster
▼ + stars: | 2022-11-08 | by ( ) www.reuters.com time to read: +2 min

Nov 8 (Reuters) - Vaccine maker Novavax Inc (NVAX.O) said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study. Data showed the shot, NVX-CoV2515, produced 1.6 times the amount of neutralizing antibodies in people who had previously not been exposed to COVID-19 compared to Novavax's original coronavirus vaccine. The trial included Novavax's so-called bivalent vaccine, the BA.1-tailored shot and its prototype vaccine. Novavax says the results from the study showed its Omicron-tailored shot can be changed to target a new variant vaccine if necessary. Novavax's COVID shot has not yet received approval in the United States as a second booster dose.

☆ Housing isn't getting any cheaper. But an expensive mortgage is not the only thing making homes so unaffordable.
▼ + stars: | 2022-11-04 | by ( Phil Rosen | ) www.businessinsider.com time to read: +6 min

Everyone's talking about how the Fed's rate hikes have sent mortgage rates skyrocketing. But even as mortgage rates have climbed above 7%, my colleague Alcynna Lloyd and I report that there's more to the story. The general gist is that the surge in home prices — fueled by the low rates of the pandemic era — hasn't come down as fast as mortgage rates have come up. There's a saying, "all real estate is local." This self-made millionaire who made his money investing in real estate isn't interested in taking out a mortgage right now.

☆ Pfizer releases more data indicating omicron boosters are better than old Covid shots
▼ + stars: | 2022-11-04 | by ( Spencer Kimball | ) www.cnbc.com time to read: +4 min

Pfizer and BioNTech also found that people with and without prior Covid infections had a significant increase in their antibody levels after the omicron boosters. Pfizer and BioNTech released more human data Friday indicating the omicron BA.5 boosters perform better than the old Covid shots. Pfizer and BioNTech released the first human data in October showing the omicron boosters trigger a better immune response. They found the new boosters and the old shots performed about the same against omicron BA.5. The scientific community and public health officials are closely following data on the boosters because the FDA authorized them without direct human data.

☆ Moderna Cuts Outlook Amid Supply Constraints
▼ + stars: | 2022-11-03 | by ( Sabela Ojea | ) www.wsj.com time to read: 1 min

Moderna said higher costs and a decline in demand for its Omicron-targeting Covid-19 doses hit its performance in its latest quarter. Moderna Inc. said third-quarter revenue fell by nearly a third and cut its outlook as supply constraints sap up to $3 billion in sales this year. The Cambridge, Mass.-based pharmaceutical company on Thursday said higher costs and a decline in demand for its Omicron-targeting Covid-19 doses also hit its performance.

☆ Stocks making the biggest moves premarket: Restaurant Brands, Under Armour, Peloton and more
▼ + stars: | 2022-11-03 | by ( Peter Schacknow | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines before the bell:Restaurant Brands (QSR) – The parent of Burger King, Tim Hortons and Popeyes saw its stock rally 4% in premarket trading after the company reported better-than-expected quarterly results. Under Armour (UAA) – Under Armour jumped 4.2% in premarket action after the apparel maker reported better-than-expected earnings for its latest quarter, along with revenue that was roughly in line with Street forecasts. The chip maker also reported quarterly revenue and profit that were in line with Wall Street forecasts. The forecast is weighing on shares despite Roku reporting better-than-expected revenue and a larger-than-expected number of active accounts. eBay (EBAY) – eBay surged 6.7% in premarket trading after the e-commerce company reported better-than-expected results for its latest quarter, boosted by sales of refurbished goods and luxury offerings.

☆ Three stock lunch: PTON, AMZN and MRNA
▼ + stars: | 2022-11-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThree stock lunch: PTON, AMZN and MRNAAptus Capital's David Wagner joins 'Power Lunch' to present his picks for the three stock lunch: Peloton, Amazon, and Moderna.

☆ Moderna cuts COVID vaccine sales forecast on supply woes, shares tumble
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +1 min

Nov 3 (Reuters) - Moderna Inc (MRNA.O) cut its annual sales forecast for its COVID-19 vaccine on Thursday, citing short-term supply constraints that would push some deliveries out to next year, sending its shares down nearly 16% before the bell. It now expects vaccine sales of $18 billion and $19 billion this year compared to a prior forecast of $21 billion. Some U.S. pharmacies in September had reported that government supply of Moderna's updated shot remains limited, causing appointments for the product to vary across the country. Moderna's forecast cut comes just two days after rival Pfizer Inc's (PFE.N) quarterly sales of its COVID-19 vaccine exceeded market expectations and the drugmaker raised the full-year sales forecast for its shots. The vaccine maker reported sales of $3.36 billion in the third quarter, missing Wall Street estimates of $3.53 billion.

☆ Pfizer, BioNTech start COVID-flu combination vaccine study
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +1 min

Nov 3 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N) and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday. The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored COVID-19 booster shot. The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot's safety, tolerability and immunogenicity, or the ability to generate immune response. Rivals Moderna Inc (MRNA.O) and Novavax Inc (NVAX.O) are also developing combination vaccines targeting both COVID-19 and influenza. read moreReporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza and Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

☆ Moderna shares plummet after Covid vaccine maker lowers 2022 sales outlook
▼ + stars: | 2022-11-03 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

Moderna on Thursday lowered its 2022 sales guidance for its Covid-19 vaccine after missing Wall Street expectations for the third quarter. The Boston biotech company said it now expects to book $18 billion to $19 billion in revenue from its Covid vaccine this year, down from its previous guidance of $21 billion. Moderna said some Covid vaccine deliveries have been pushed into 2023 due to supply constraints. Moderna's third quarter revenue came in at $3.36 billion, down 32% from the same period in 2021. It is also expecting phase three immune response data from its flu vaccine candidate in the first quarter of 2023.

☆ Morning Bid: Slower, higher, longer
▼ + stars: | 2022-11-03 | by ( ) www.reuters.com time to read: +3 min

A look at the day ahead in U.S. and global markets from Mike Dolan. U.S. Treasury yields are on the rise again as Fed rate futures now expect a terminal rate as high as 5.15% by May, with pricing for end-2023 rates just shy of 5% too - half a point higher than where futures had priced the terminal rate just one month ago. European Central Bank President Christine Lagarde said the ECB must be "attentive" to Fed policy decisions as it influences global markets - but it cannot just mirror moves in Washington. In banking, Morgan Stanley is expected to start a new round of layoffs around the world over the coming weeks. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

☆ The Unlikeliest Household Name
▼ + stars: | 2022-11-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe Unlikeliest Household NameThe power of messenger RNA is obvious now, the basis of the Covid vaccines that blunted the force of the pandemic. It wasn't so obvious in 2015, when Moderna topped CNBC's annual Disruptor 50 list. The CEO joins us to discuss what became one of the greatest medical races in history and what lies ahead for a now decade-old company that's fighting to protect its patented technology.

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion, and said new deals and drugs in development should help replace future declining vaccine sales and lost revenue from patent expirations. Sales of the Pfizer/BioNTech COVID vaccine are down from pandemic highs as many countries have neared the end of their primary vaccination campaigns. Third-quarter sales of the COVID vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion. However, $7.51 billion in sales of Paxlovid, the company's COVID-19 antiviral treatment, fell short of estimates of $7.66 billion. Pfizer reported adjusted earnings of $1.78 per share in the third quarter, beating analysts' estimates by 39 cents.

☆ Pfizer boosts COVID vaccine sales forecast by $2 bln
▼ + stars: | 2022-11-01 | by ( Manas Mishra | ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - Pfizer Inc (PFE.N) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker's shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion.

☆ Dentsply Sirona Finds Improper Accounting for Incentives, Plans to Restate Earnings
▼ + stars: | 2022-11-01 | by ( Mark Maurer | ) www.wsj.com time to read: +7 min

The company said it overstated net sales and net income for the nine-month period ended Sept. 30, 2021 by $35 million and $27 million, respectively. Dentsply also said it overstated its net sales and net income for the 2021 fiscal year by $20 million and $10 million, respectively. It also booked a combined $108 million in related net sales during those quarters. As a result, Dentsply overstated net sales in the third quarter of 2021 by roughly $4 million, which should have been recorded the following quarter. A re-evaluation of controls and procedures identified one or more material weaknesses in the company’s internal controls over financial reporting.

☆ These global stocks surged last week, and analysts give them further upside
▼ + stars: | 2022-10-31 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Moderna, on the other hand, has 40% upside on average, according to analysts covering the stock. Over 60% of analysts covering Centene give it a buy rating, and it has 18% average upside, according to FactSet data. It jumped 16% last week week. Japanese electronics firm Ibiden surged over 20% last week, and analysts give it 23% upside on average. Analysts covering it give it an average upside of nearly 30%.

☆ New RSV vaccines may soon put an end to rough seasons
▼ + stars: | 2022-10-31 | by ( Brenda Goodman | ) edition.cnn.com time to read: +15 min

The monoclonal antibody, Synagis, is given monthly during RSV season to protect preemies and other high-risk babies. In the failed RSV vaccine trial, the chemical the researchers used to deactivate the virus denatured its proteins – essentially flattening them. Four companies have RSV vaccines for adults in the final phases of human trials: Pfizer and GSK are testing vaccines for pregnant women as well as seniors. Janssen, Pfizer and GSK each appear effective at preventing infections in adults for the first RSV season after the vaccine. The vaccines for pregnant women are meant to get newborns through their first RSV season.

☆ The Fed may have to blow up the economy to get inflation under control
▼ + stars: | 2022-10-30 | by ( Paul R. La Monica | ) edition.cnn.com time to read: +7 min

Jobs report also on tapThe Fed meeting takes place just two days before the nation will get its next report card on the labor market. Another jobs report, from payroll processor ADP, is also due out next week, and this one looks just at Corporate America. The government said in the September jobs report that average hourly earnings rose 5% in the past 12 months. The Fed typically prefers to see wage growth in the 2% to 3% annual range as a sign that inflation is under control. Discovery, Starbucks (SBUX), PayPal (PYPL), Amgen (AMGN) and Block (SQ)Friday: US jobs report; earnings from Cardinal Health (CAH), Duke Energy (DUK) and Hershey (HSY)

The back half of the earnings season gets underway this week, with key companies across different sectors set to report. FactSet data shows that slightly more than 70% of the S & P 500 that have reported earnings have beaten earnings expectations. Tuesday Advanced Micro Devices is set to report earnings after the bell, followed by a conference call at 5 p.m. Wednesday Yum Brands is set to report earnings before the bell, with management holding a call at 8:15 a.m. EBay is set to report earnings after the bell, followed by a call at 5 p.m.

☆ Three buys and a bail: AbbVie, Eli Lilly, Humana and Moderna
▼ + stars: | 2022-10-28 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThree buys and a bail: AbbVie, Eli Lilly, Humana and ModernaGina Sanchez, Lido Advisors chief market strategist, joins 'The Exchange' to discuss three stocks Sanchez is interested in buying and one the strategist is bailing on.

Search resuls for: "modernă"

25 mentions found